false
Hamburger Menu
Catalog
JTO Clinical and Research Reports, February 2022, ...
JTO Clinical and Research Reports, February 2022, Volume 3, Issue 2
Journal | English | 2022
Create Account
Availability
On-Demand
Cost
$0.00
Credit Offered
No Credit Offered
Table of Contents
Original Articles:
A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC
Effects of Ethnicity on Outcomes of Patients With
EGFR
Mutation–Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical Resection
Thoracic Radiotherapy in Limited-Stage SCLC—a Population-Based Study of Patterns of Care in Norway From 2000 Until 2018
Real-World Treatment Patterns and Outcomes Among Patients With Metastatic NSCLC Previously Treated With Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Inhibitors
Performance of an RNA-Based Next-Generation Sequencing Assay for Combined Detection of Clinically Actionable Fusions and Hotspot Mutations in NSCLC
Prognostic Stratification According to Size and Dominance of Radiologic Solid Component in Clinical Stage IA Lung Adenocarcinoma
Case Reports
Cytokine Release Syndrome and Immune-Related Pneumonitis Associated With Tumor Progression in a Pulmonary Pleomorphic Carcinoma Treated With Nivolumab Plus Ipilimumab Treatment: A Case Report
Successful Tepotinib Challenge After Capmatinib-Induced Interstitial Lung Disease in a Patient With Lung Adenocarcinoma Harboring
MET
Exon 14 Skipping Mutation: Case Report
Composite Clonal Analysis Reveals Transition of NSCLC Subtypes Through Accumulation of Gene Mutations: A Case Report
“Real” Tumor-Spread Through Air Spaces of Lung Adenocarcinoma Presented Intrapulmonary Metastases Through Bronchiole Air Spaces: A Case Report
Pulmonary Adenoid Cystic Carcinoma Presenting Late With Intrapericardial Extension: Case Report
Brief Reports
Brief Report: Medical Assistance in Dying in Patients With Lung Cancer
YES1
and
MYC
Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs
Discussion
Impact of the Coronavirus Disease 2019 Pandemic on Global Lung Cancer Clinical Trials: Why It Matters to People With Lung Cancer
About JTO Clinical and Research Reports
JTO Clinical and Research Reports
is the official open access journal of the
International Association for the Study of Lung Cancer
. It aims to complement the
Journal of Thoracic Oncology
by offering authors a gold open access publication option and publishing the following article types in particular:
Phase I trials
Well performed single-arm phase II trials
Subset analyses of published trials
Impactful retrospective Studies
Database analysis
Large institutional series
High-quality case reports
Region-specific clinical trials
Subspecialty thoracic oncology studies
Selected high-quality meeting reports
As an open access journal with no subscription charges,
JTO CRR
requires authors to pay a
fee
to cover the costs associated with publication. This ensures your article will be immediately and permanently free to access by everyone.
×
JTO Clinical and Research Reports, February 2022, Volume 3, Issue 2 Course List
Login
User Login
Continue with Google
OR
Email
Password
Logging In…
Create Account
Forgot Password
×
Please select your language
1
English